Rasagiline
Rasagiline Vipharm contains the active substance rasagiline and is used in adults to treat Parkinson's disease. It can be taken with or without levodopa (another medicine used to treat Parkinson's disease).
In Parkinson's disease, there is a loss of cells that produce dopamine in the brain. Dopamine is a neurotransmitter in the brain that has an effect on movement control. Rasagiline Vipharm increases and maintains dopamine levels in these areas.
While taking Rasagiline Vipharm, you must not take the following medicines:
There must be at least 14 days between stopping Rasagiline Vipharm and starting MAOIs or pethidine.
Before starting Rasagiline Vipharm, discuss with your doctor or pharmacist:
Tell your doctor if you or your family/carer notice that you are developing unusual behaviors such as compulsions, obsessive thoughts, or urges, which are beyond your control, including:
gambling, excessive shopping or spending, impulsive behavior, or an abnormally high sex drive, as these can be signs of impulse control disorders. Your doctor may need to adjust or stop your treatment (see section 4).
Rasagiline Vipharm may cause you to feel drowsy or fall asleep suddenly during the day, especially if you are also taking other medicines for Parkinson's disease.
Rasagiline Vipharm should not be used in children and adolescents. Therefore, it is not recommended for patients under 18 years of age.
Tell your doctor or pharmacist about all the medicines you are taking, or have recently taken, and about any you plan to take.
Particularly, tell your doctor if you are taking any of the following:
Avoid taking Rasagiline Vipharm with antidepressants containing fluoxetine or fluvoxamine.
Do not start Rasagiline Vipharm until at least 5 weeks after stopping fluoxetine.
Do not start fluoxetine or fluvoxamine until at least 14 days after stopping Rasagiline Vipharm.
Tell your doctor or pharmacist if you smoke or intend to stop smoking. Smoking may decrease the amount of rasagiline in your blood.
If you are pregnant, think you may be pregnant, or plan to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant, you should not take Rasagiline Vipharm, as it is not known whether rasagiline is harmful to the unborn baby.
Before driving or using machines, consult your doctor, as Parkinson's disease and rasagiline may affect your ability to perform these activities. Rasagiline may cause dizziness or drowsiness. It may also cause sudden sleep episodes.
These effects may be more pronounced when taking other medicines for Parkinson's disease or other medicines that cause drowsiness, or if you drink alcohol while taking Rasagiline Vipharm. Patients who have experienced drowsiness or sudden sleep episodes before or while taking Rasagiline Vipharm should not drive or use machines (see section 2).
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose of Rasagiline Vipharm is 1 tablet of 1 mg taken by mouth once a day. Rasagiline Vipharm can be taken with or without food.
If you think you have taken more tablets than you should, contact your doctor or pharmacist immediately. Take the carton or blister pack with you to show the doctor or pharmacist.
Symptoms reported after an overdose of Rasagiline Vipharm include: mildly euphoric mood (mild mania), severely high blood pressure, and serotonin syndrome (see section 4).
Do not take a double dose to make up for a forgotten dose. Take the next dose of Rasagiline Vipharm at the usual time.
Do not stop taking Rasagiline Vipharm without first discussing it with your doctor.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Rasagiline Vipharm can cause side effects, although not everybody gets them.
If you experience any of the following side effects, contact your doctor immediately. You may need urgent medical attention or treatment:
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Frequency not known: cannot be estimated from the available data
If you experience any side effects, including those not listed in this leaflet, tell your doctor, pharmacist, or nurse.
Side effects can be reported to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw, Poland
Phone: +48 22 49 21 301, Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, bottle, or blister after "EXP". The expiry date refers to the last day of that month.
Blisters:No special storage precautions.
Store in the original blister to protect from light.
Bottles:Do not store above 30°C. Store in the original bottle to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
The active substance is rasagiline. Each tablet contains 1 mg of rasagiline (as rasagiline tartrate).
The other ingredients are: microcrystalline cellulose, maize starch, colloidal anhydrous silica, magnesium stearate.
White or almost white, round, flat tablets with beveled edges and engraved with "1" on one side, 8 mm in diameter.
Blisters:OPA/Aluminum/PVC/Aluminum blisters in cardboard boxes, containing 7, 10, 28, 30, 100, or 112 tablets.
Bottles:HDPE bottle with LDPE cap and a desiccant, in a cardboard box, containing 30 tablets.
Not all pack sizes may be marketed.
Vipharm S.A., ul. A. i F. Radziwiłłów 9, 05-850 Ożarów Mazowiecki, Poland
Phone: +48 22 679 51 35, Fax: +48 22 678 92 87, e-mail: vipharm@vipharm.com.pl
Genepharm S.A., 18 km Marathon Avenue, 15351 Pallini Attiki, Greece
Poland: RASAGILINE VIPHARM
Hungary: RASAGILINE VIPHARM 1 mg tabletta
Slovakia: RASAGILINE VIPHARM 1 mg tablets
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.